Internal Medicine, Endocrinology, Diabetes, & Metabolism · Vero Beach, FL
NPI
1265418743
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
2
Medicare group memberships
Hospitals
2
Hospital affiliations
3745 11th Cir
Vero Beach, FL, 32960
Phone (772) 589-0580
Groups this clinician bills Medicare through
Medicare paid, 2024
$111K
1,203 services
Medicare patients, 2024
547
Average age 76
Drug cost, 2024
$3.4M
6,589 prescriptions
Company payments, 2025
$46.44
From 3 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David R Biezunski was code 99214 (office e&m - established), 994 times for 423 patients. In total David R Biezunski billed 1,203 services in 7 codes, and Medicare paid $111K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2025-03-31.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 994 | 423 | $94.18 | $94K |
| 99213 Office E&M - Established | Office | 109 | 106 | $67.90 | $7,401 |
| 99204 Office E&M - New | Office | 80 | 80 | $118.02 | $9,442 |
By year: 2022 $128K for 1,479 services; 2023 $117K for 1,293 services; 2024 $111K for 1,203 services.
Medicare prescription drug claims, 2024
In 2024, the drug David R Biezunski prescribed most often to Medicare patients was Levothyroxine Sodium, with 777 prescriptions and refills. In total David R Biezunski wrote 6,589 Medicare prescriptions that cost $3.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 777 | 2,161 | 209 | $10K |
| Metformin Hcl Generic | 563 | 1,621 | 161 | $4,838 |
| Ozempic Semaglutide | 542 | 890 | 123 | $823K |
| Mounjaro Tirzepatide | 334 | 463 | 73 | $490K |
| Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog | 225 | 582 | 76 | $242K |
| Jardiance Empagliflozin | 207 | 517 | 64 | $286K |
| Nano 2nd Gen Pen Needle Pen Needle, Diabetic | 200 | 565 | 92 | $17K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 190 | 449 | 58 | $44K |
| Tresiba Flextouch U-200 Insulin Degludec | 176 | 497 | 61 | $242K |
| Atorvastatin Calcium Generic | 166 | 472 | 47 | $1,757 |
| Trulicity Dulaglutide | 158 | 249 | 36 | $240K |
| Glimepiride Generic | 152 | 456 | 48 | $1,355 |
| Synthroid Levothyroxine Sodium | 143 | 386 | 42 | $13K |
| Ezetimibe Generic | 121 | 334 | 34 | $3,964 |
| Januvia Sitagliptin Phosphate | 108 | 250 | 26 | $134K |
Brand drugs: 3,584 claims; generic drugs: 2,555 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David R Biezunski $46.44 ($46.44 in general payments such as food, travel and fees) from 3 companies. The largest payer was Boehringer Ingelheim Pharmaceuticals, Inc. with $18.85.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.